Follow
Olivier Nolan-Stevaux or Olivier Stevaux
Olivier Nolan-Stevaux or Olivier Stevaux
Verified email at gilead.com - Homepage
Title
Cited by
Cited by
Year
A revised picture of the E2F transcriptional network and RB function
O Stevaux, NJ Dyson
Current opinion in cell biology 14 (6), 684-691, 2002
5842002
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation
O Nolan-Stevaux, J Lau, ML Truitt, GC Chu, M Hebrok, ...
Genes & development 23 (1), 24-36, 2009
4612009
Native E2F/RBF complexes contain Myb-interacting proteins and repress transcription of developmentally controlled E2F target genes
M Korenjak, B Taylor-Harding, UK Binné, JS Satterlee, O Stevaux, ...
Cell 119 (2), 181-193, 2004
3202004
Cell cycle-dependent and cell cycle-independent control of transcription by the Drosophila E2F/RB pathway
DK Dimova, O Stevaux, MV Frolov, NJ Dyson
Genes & development 17 (18), 2308-2320, 2003
2982003
Functional antagonism between E2F family members
MV Frolov, DS Huen, O Stevaux, D Dimova, K Balczarek-Strang, ...
Genes & development 15 (16), 2146-2160, 2001
2022001
Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies
O Nolan-Stevaux, W Zhong, S Culp, K Shaffer, J Hoover, ...
PloS one 7 (12), e50920, 2012
1452012
Distinct mechanisms of E2F regulation by Drosophila RBF1 and RBF2
O Stevaux, D Dimova, MV Frolov, B Taylor‐Harding, E Morris, N Dyson
The EMBO journal, 2002
1182002
Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell–recruiting antibody optimized for cytotoxicity and cytokine release
CL Zuch de Zafra, F Fajardo, W Zhong, MJ Bernett, US Muchhal, ...
Clinical Cancer Research 25 (13), 3921-3933, 2019
1012019
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
P Olson, GC Chu, SR Perry, O Nolan-Stevaux, D Hanahan
Proceedings of the National Academy of Sciences 108 (49), E1275-E1284, 2011
882011
The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer
P Deegen, O Thomas, O Nolan-Stevaux, S Li, J Wahl, P Bogner, F Aeffner, ...
Clinical Cancer Research 27 (10), 2928-2937, 2021
512021
Retinoblastoma family 2 is required in vivo for the tissue-specific repression of dE2F2 target genes
O Stevaux, DK Dimova, JY Ji, NS Moon, MV Frolov, NJ Dyson
Cell Cycle 4 (9), 1272-1280, 2005
492005
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
B Belmontes, DV Sawant, W Zhong, H Tan, A Kaul, F Aeffner, SA O’Brien, ...
Science Translational Medicine 13 (608), eabd1524, 2021
482021
Measurement of cancer cell growth heterogeneity through lentiviral barcoding identifies clonal dominance as a characteristic of in vivo tumor engraftment
O Nolan-Stevaux, D Tedesco, S Ragan, M Makhanov, A Chenchik, ...
PloS one 8 (6), e67316, 2013
412013
G1 cyclin-dependent kinases are insufficient to reverse dE2F2-mediated repression
MV Frolov, O Stevaux, NS Moon, D Dimova, EJ Kwon, EJ Morris, ...
Genes & development 17 (6), 723-728, 2003
392003
Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes
O Nolan-Stevaux, MC Truitt, JC Pahler, P Olson, C Guinto, DC Lee, ...
Genes & cancer 1 (2), 125-141, 2010
352010
Antibody constructs for CD70 and CD3
T Raum, C Blümel, W Deisting, P Hoffmann, R Lutterbüse, E Nahrwold, ...
US Patent 10,851,170, 2020
182020
Preclinical characterization of AMG 424, a novel humanized T cell-recruiting bispecific anti-CD3/CD38 antibody
C de Zafra, M Balazs, F Fajardo, L Liang, W Zhong, A Henn, MJ Bernett, ...
Blood 130, 500, 2017
172017
Heterodimeric antibodies that bind cd3 and cd38
JL Stevens, M Balazs, O Nolan-Stevaux, G Moore, J Desjarlais, ...
US Patent App. 15/779,325, 2018
142018
Abstract DDT02-03: AMG 509: A novel, humanized, half-Life extended, bispecific STEAP1 × CD3 T cell recruiting XmAb® 2+1 antibody
O Nolan-Stevaux
Cancer research 80 (16_Supplement), DDT02-03-DDT02-03, 2020
132020
Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway
Y Shen, JS Eng, F Fajardo, L Liang, C Li, P Collins, D Tedesco, ...
Journal for immunotherapy of cancer 10 (3), 2022
122022
The system can't perform the operation now. Try again later.
Articles 1–20